ASCO GU 2022 video: Simon Crabb outlines the results of the rucaparib arm of the ATLANTIS trial of maintenance therapy in patients with metastatic

Nazli Dizman shares her highlights of the renal cell carcinoma presentations at the 2021 Genitourinary Cancers Symposium prostate cancer track, including the SWOG 1500 and CLEAR trials.

Clinical insights from Shilpa Gupta and Petros Grivas on ASCO GU 2021 trial data for metastatic urothelial cancer: EV-301, EV-201,TITAN-TCC, and

Dose intensification does not improve the outcomes of salvage radiotherapy after radical prostatectomy, the SAKK 09/10 investigators have reported at the 2021 Genitourinary Cancers Symposium.

Axel Merseburger discusses the key abstracts in the 2021 Genitourinary Cancers Symposium prostate cancer track, including TITAN, TheraP, and ACIS, and shares his thoughts on how these findings may inform clinical practice.

“The results from this cohort support the ongoing CheckMate 7DX phase 3 trial of nivolumab plus docetaxel for metastatic CRPC,” concluded the presenter. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group 2021 Genitourinary Cancers Symposium; 11–13 February (Abstract 10) 2021 Genitourinary Cancers Symposium; 11–13 February (Abstract 12)

But he also cautioned that the findings “might not be applicable to men selected less carefully.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group 2021 Genitourinary Cancers Symposium; 11–13 February Lancet 2021; doi:10.1016/S0140-6736(21)00237-3

Questioning whether the savolitinib arm in SWOG 1500 might have performed better had the patients been selected for MET mutations, Berg concluded that “we’ll have to wait for further exploratory analysis regarding MET mutation status to tease out these differences.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group 2021 Genitourinary Cancers Symposium; 11–13 February Lancet 2021; doi:10.1016/S0140-6736(21)00152-5

Clinical insights from Petros Grivas and Shilpa Gupta on ASCO GU 2021 trial data for nonmetastatic urothelial cancer: POUT, CheckMate 274, SAKK

Highlighting that overall survival was not examined in the current analysis, Alumkal added that “it is important to know whether this signature showed consistency across endpoints, including for overall survival.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group 2021 Genitourinary Cancers Symposium; 11–13 February

In light of these limitations and clinical insights from other studies of combined or sequential androgen receptor signaling inhibitor treatments, “I do not believe results from ACIS change practice at this time,” he concluded. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group 2021 Genitourinary Cancers Symposium; 11–13 February

Andrea Apolo presents the final analysis of a phase 1 study of cabozantinib plus nivolumab, with or without ipilimumab, in metastatic GU tumors.

He continued: “Such studies could establish a highly individualized de-intensified approach to treat prostate cancer, conditioned on a below the multimodality threshold strategy.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group 2021 Genitourinary Cancers Symposium; 11–13 February

Therefore, “ CDKN2A alteration status may serve as a predictive biomarker” in this patient population, they said in the abstract of a poster presented at the 2021 Genitourinary Cancers Symposium.

“These trials establish that [immuno-oncology]–TKI combination therapy is now standard of care and our second-line choice is less clear, therefore data is needed on the most suitable order of therapy for the entire population as well as specific groups in the future,” she concluded. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group 2021 Genitourinary Cancers Symposium; 11–13 February N Engl J Med 2021; doi:10.1056/NEJMoa2035716

The data were published in The New England Journal of Medicine to coincide with their presentation at the 2021 Genitourinary Cancers Symposium by Thomas Powles, from Barts Cancer Institute in London, UK.

Sumanta Pal provides an overview of the phase 2 SWOG 1500 study pitting the MET inhibitors cabozantinib, crizotinib, and savolitinib against sunitinib for the treatment of metastatic papillary renal cell carcinoma.

“Overall, these results support the consideration of avelumab [first-line] maintenance as a potential new standard of care in Japanese patients with advanced UC that has not progressed with [first-line] platinum-containing chemotherapy,” concluded Tsuchiya and team. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group This independent news story was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany 2021 Genitourinary Cancers Symposium; 11–13 February (Abstract 438) 2021 Genitourinary Cancers Symposium; 11–13 February (Abstract 425)

Toni Choueiri, from the Dana-Farber Cancer Institute in Boston, Massachusetts, USA, presented the findings at the 2021 Genitourinary Cancers Symposium.

Bajorin also reported that health-related quality of life – as assessed by the EORTC-QLQ-C30 global score – did not deteriorate in the nivolumab versus placebo study arms in either the ITT or PD-L1-positive populations. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group 2021 Genitourinary Cancers Symposium; 11–13 February